Therefore, it is possible that DTMB alleviates the pathological condition of Alzheimer’s disease by reducing the peripheral inflammation caused by metabolic dysfunction through PPAR signaling. This evidence concerns the gene PPARA and early-onset autosomal dominant Alzheimer disease.